{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-023224","form_type":"8-K","ticker":"ACET","cik":"0001720580","company_name":"Adicet Bio, Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.876898+00:00","generated_at":"2026-06-22T04:05:49.255920+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Adicet Bio Q3 net loss $22M; ADI-001 shows 78% ORR/CR, pivotal program planned H1 2023","bullets":["Net loss of $22.0M ($0.53 per share) vs $14.0M in Q3 2021; R&D expenses rose to $16.6M.","Cash and cash equivalents $282.7M as of Sep 30, 2022; runway into first half of 2025.","ADI-001 Phase 1 data: 78% ORR and CR (7/9) in relapsed/refractory B-cell NHL; 100% in prior CAR-T patients.","Expects to initiate a potentially pivotal program for ADI-001 in the first half of 2023.","In-house manufacturing in Redwood City expected operational in Q4 2022; R&D webcast Nov 10, ASH update Dec 11."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-023224","json":"https://secwatch.observer/filing/0000950170-22-023224.json","markdown":"https://secwatch.observer/filing/0000950170-22-023224.md","text":"https://secwatch.observer/filing/0000950170-22-023224.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720580/000095017022023224/0000950170-22-023224-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720580/000095017022023224/acet-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T04:05:49.255920+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7043f7fc38b059a2d5c59af8a79add60c116f1d0","claim":"Adicet Bio, Inc. reported the third quarter ended September 30, 2022 results: net income Net loss for the three months ended September 30, 2022 was $22.0 million, or a net loss of $0.53 per basic and diluted s, EPS net loss of $0.53 per basic and diluted share.","evidence_excerpt":"Net loss for the three months ended September 30, 2022 was $22.0 million, or a net loss of $0.53 per basic and diluted share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1720580/000095017022023224/0000950170-22-023224-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Net income","value":"Net loss for the three months ended September 30, 2022 was $22.0 million, or a net loss of $0.53 per basic and diluted s"},{"label":"EPS","value":"net loss of $0.53 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}